Saluda Medical initiated the U.S. commercialization of the Evoke spinal cord stimulator, the devicemaker said Dec. 15.
Evoke is the only FDA-approved therapy with 24-month follow-up from a clinical study, according to a news release. A full commercial release is scheduled for 2023.
Evoke uses closed-loop technology and is designedto treat trunk and/or limb pain. The device earned FDA approval in March.